Insider Selling: BioLife Solutions, Inc. (NASDAQ:BLFS) CMO Sells 3,500 Shares of Stock

BioLife Solutions, Inc. (NASDAQ:BLFSGet Rating) CMO Todd Berard sold 3,500 shares of the stock in a transaction dated Monday, January 23rd. The stock was sold at an average price of $25.01, for a total transaction of $87,535.00. Following the sale, the chief marketing officer now owns 119,265 shares in the company, valued at $2,982,817.65. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Todd Berard also recently made the following trade(s):

  • On Wednesday, January 18th, Todd Berard sold 6,500 shares of BioLife Solutions stock. The stock was sold at an average price of $25.04, for a total transaction of $162,760.00.
  • On Wednesday, December 28th, Todd Berard sold 501 shares of BioLife Solutions stock. The shares were sold at an average price of $16.90, for a total transaction of $8,466.90.
  • On Thursday, November 10th, Todd Berard sold 50 shares of BioLife Solutions stock. The stock was sold at an average price of $23.16, for a total value of $1,158.00.

BioLife Solutions Price Performance

Shares of BLFS traded down $0.85 during trading hours on Wednesday, reaching $24.15. The stock had a trading volume of 198,383 shares, compared to its average volume of 338,355. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.76 and a current ratio of 3.68. BioLife Solutions, Inc. has a 12 month low of $10.40 and a 12 month high of $31.11. The stock has a market capitalization of $1.03 billion, a PE ratio of -9.74 and a beta of 1.75. The company’s 50-day moving average is $20.43 and its two-hundred day moving average is $21.31.

BioLife Solutions (NASDAQ:BLFSGet Rating) last issued its earnings results on Wednesday, November 9th. The medical equipment provider reported ($0.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.03). BioLife Solutions had a negative return on equity of 7.50% and a negative net margin of 67.70%. The firm had revenue of $40.75 million during the quarter, compared to analyst estimates of $41.63 million. Research analysts expect that BioLife Solutions, Inc. will post -0.63 EPS for the current year.

Institutional Investors Weigh In On BioLife Solutions

Several hedge funds have recently added to or reduced their stakes in BLFS. Stephens Inc. AR increased its position in BioLife Solutions by 4.2% in the 4th quarter. Stephens Inc. AR now owns 144,249 shares of the medical equipment provider’s stock valued at $2,625,000 after acquiring an additional 5,797 shares during the period. Bank of New York Mellon Corp grew its stake in shares of BioLife Solutions by 4.5% in the third quarter. Bank of New York Mellon Corp now owns 350,690 shares of the medical equipment provider’s stock worth $7,979,000 after purchasing an additional 15,206 shares during the last quarter. Teachers Retirement System of The State of Kentucky acquired a new stake in BioLife Solutions in the third quarter valued at $212,000. Captrust Financial Advisors raised its position in BioLife Solutions by 136.7% during the 3rd quarter. Captrust Financial Advisors now owns 9,348 shares of the medical equipment provider’s stock worth $213,000 after purchasing an additional 5,399 shares during the last quarter. Finally, Fred Alger Management LLC lifted its holdings in BioLife Solutions by 21.9% during the 3rd quarter. Fred Alger Management LLC now owns 2,163,476 shares of the medical equipment provider’s stock worth $49,219,000 after buying an additional 388,642 shares during the period. 89.82% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities analysts have recently commented on the company. Stephens lowered their price target on BioLife Solutions to $31.00 in a report on Wednesday, November 16th. StockNews.com raised BioLife Solutions to a “sell” rating in a research note on Monday, November 21st.

BioLife Solutions Company Profile

(Get Rating)

BioLife Solutions, Inc develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.

Read More

Insider Buying and Selling by Quarter for BioLife Solutions (NASDAQ:BLFS)

Receive News & Ratings for BioLife Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLife Solutions and related companies with MarketBeat.com's FREE daily email newsletter.